Flavopiridol hydrochloride
(Synonyms: (-)-2-(2-氯苯基)-5,7-二羟基-8-[(3S,4R)-3-羟基-1-甲基-4-哌啶基]-4H-1-苯并吡喃-4-酮盐酸盐,Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride) 目录号 : GC16425
An inhibitor of cyclin-dependent kinases
Cas No.:131740-09-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Kinase experiment: |
Briefly, lysates containing approximately 3×106 cells are incubated with 50 μM LEVD-AFC (caspase 4 substrate) or LETD-AFC (caspase 8 substrate) containing 10 mM dithiothretiol (DTT). Caspase 4 activity is measured one hour after addition of substrate and caspase 8 activity is measured 30 minutes after addition of substrate. Release of free AFC is measured with a Beckman-Coulter DTX 880 multimode detector. |
|
Cell experiment: |
The cells treated with flavopiridol are washed after 4 hours with PBS and resuspended in regular growth medium (RPMI 1640) supplemented with 10% human serum and antibiotics for the remainder of the incubation time. In the case of flavopiridol/chloroquine samples, chloroquine is re-added in the fresh media after flavopiridol is washed at 4 hours. For all the other conditions, cells are incubated with the respective drugs for 24 hours continuously. |
|
References: [1]. Mahoney E, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood. 2012 Aug 9;120(6):1262-1273. |
|
Flavopiridol hydrochloride is a selective inhibitor of CDK1, CDK2, CDK4 and CDK6 with IC50 value all ~41 nM as well as CDK7 with 300nM [1] [2] [3].
CDKs are protein kinase families which involve in the process of regulating transcription, mRNA processing, cell differentiation and cell cycle. It has been shown that CDKs are abnormally expressed in a variety of cells [3].
Flavopiridol hydrochloride is a potent CDK inhibitor and is different from UCN-01. When tested with breast carcinoma cell line MCF-7, flavopiridol hydrochloride treatment showed high inhibitory ability to arrest cell cycle at G1 phase through inhibiting CDK2 and CDK4 [1]. Treated seven lymphoma cell lines with flavopiridol hydrochloride at the concentration of 400 nM, it showed that flavopiridol hydrochloride induced cells apoptosis by inhibiting CDK4, CDK6, CDK7 or CDK9 which in turn inhibited Rb phosphorylation, anti-apoptotic preteins (Mcl-1 and XIAP) [4].
In mouse model with HL-60 subcutaneous xenograft, administration of flavopiridol hydrochloride (7.5 mg/kg) intravenously induced advanced stage animals complete regression with 91.67% and remained disease-free several months after one course of flavopiridol treatment [5].
It has also been reported that flavopiridol hydrochloride inhibited epidermal growth factoe receptor and protein kinase A with IC50 value of 21 and 122 μM, respectively [3].
References:
[1]. Carlson, B.A., et al., Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res, 1996. 56(13): p. 2973-8.
[2]. Losiewicz, M.D., et al., Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun, 1994. 201(2): p. 589-95.
[3]. Senderowicz, A.M., The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist, 2002. 7 Suppl 3: p. 12-9.
[4]. Ema, Y., et al., Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines. Vet Comp Oncol, 2015.
[5]. Arguello, F., et al., Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood, 1998. 91(7): p. 2482-90.
| Cas No. | 131740-09-5 | SDF | |
| 别名 | (-)-2-(2-氯苯基)-5,7-二羟基-8-[(3S,4R)-3-羟基-1-甲基-4-哌啶基]-4H-1-苯并吡喃-4-酮盐酸盐,Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride | ||
| 化学名 | 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one;hydrochloride | ||
| Canonical SMILES | CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl | ||
| 分子式 | C21H21Cl2NO5 | 分子量 | 438.3 |
| 溶解度 | ≥ 21.9mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2815 mL | 11.4077 mL | 22.8154 mL |
| 5 mM | 0.4563 mL | 2.2815 mL | 4.5631 mL |
| 10 mM | 0.2282 mL | 1.1408 mL | 2.2815 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。